Executive Director & Global Head, Emerging Science & Innovation Lead – Inflammation & Immunology, Pfizer
As Executive Director and Global Head for Inflammation & Immunology, Emerging Science & Innovation (ES&I), Arpita leads scouting of external opportunities (Idea to Candidate) and academic collaborations for the Inflammation & Immunology (I&I) research unit and the Centers for Therapeutic Innovation (CTI), at Pfizer. She also leads strategy and partnering efforts in the microbiome for Pfizer. ES&I is an externally-focused scientific team of PhDs / MDs, embedded within Pfizer research groups, that identifies late-breaking, first-in-class science forming the basis of innovative therapies, and drives related collaborations that deliver value to Pfizer, its partners, and patients. Deals for which Arpita is responsible include Evotec, Biorap, CytoReason, an equity investment and license with AnTolRx, and Theravance. Prior to Pfizer, she was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals. Arpita got her start in biotech at Angiotech Pharmaceuticals, heading the Cell Biology & Drug Screening group. She trained as an immunologist and has a PhD and MSc in Immunology from UBC and a BSc from Trinity College, UofT.